20 June 2013
Keywords: nitromed, bidil, achieves, ph, iii, goals, firm
Article | 26 July 2004
US firm NitroMed has halted a Phase III trial of BiDil (isosorbidedinitrate and hydralazine), its lead drug in development for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 August 2004
19 June 2013
© 2013 thepharmaletter.com